National Institutes of Health (NIH)

A new study from researchers at MIT shows that lack of focus after a poor night’s sleep often corresponds with a surge of cerebrospinal fluid in the brain, which usually flows while we’re asleep. “We like to think we’re in control—that willpower, caffeine, and determination can overcome a missed night of sleep,” writes Bill Murphy Jr. for Inc. “However, this research suggests otherwise. When your brain needs to clean itself, it’s going to find a way to do it, whether you’re ready for it or not.”

Researchers at MIT examined how lack of sleep can impact a person’s attention, and “found that during these moments of brain fog, a wave of cerebrospinal fluid (CSF) is released out of the brain - a process which normally occurs whilst we are sound asleep, and helps to wash away waste products built up during the day,” reports Shaheena Uddin for The Independent. 

Prof. Laura Lewis and her colleagues have discovered that momentary lapses in attention that often follow a bad night’s sleep are caused by the brain attempting to flush fluid out of its system, a process that normally occurs during sleep, reports Carissa Wong for New Scientist. “If you don’t have these waves [of fluid flowing] at night because you’re kept awake all night, then your brain starts to kind of sneak them in during the daytime, but they come with this cost of attention,” says Lewis. 

Researchers at MIT have found that momentary lapses in attention, often described as zoning out, coincide with waves of fluid flowing out of the brain, reports Ian Sample for The Guardian. “The moment somebody’s attention fails is the moment this wave of fluid starts to pulse,” says Prof. Laura Lewis. “It’s not just that your neurons aren’t paying attention to the world, there’s this big change in fluid in the brain at the same time.”

Prof. Linda Griffith and her colleagues have “developed a model of the human gut to study how the organ’s microbes interact with immune cells and regulate inflammation,” reports Gemma Conroy for Nature. Griffith and her team “have also created models for endometriosis and pancreatic cancer,” writes Conroy. 

In an effort to better understand how protein language models (PLMs) think and better judge their reliability, MIT researchers applied a tool called sparse autoencoders, which can be used to make large language models more interpretable. The findings “may help scientists better understand how PLMs come to certain conclusions and increase researchers’ trust in them," writes Andrea Luis for The Scientist. 

Prof. Pierre Azoulay speaks with WBUR’s Martha Bebinger about a new study examining the potential impact of NIH budget cuts on the development of new medicines. Azoulay and his colleagues found that “more than half of drugs approved by the FDA since 2000 used NIH-funded research that would likely not have happened if the NIH had operated with a 40% smaller budget,” Bebinger explains. 

Fierce Biotech reporter Darren Incorvaia writes that a new study by MIT researchers demonstrates how potential NIH budget cuts could endanger the development of new medications. The researchers found that if the NIH budget had been 40% smaller from 1980 to 2007, the level of NIH cuts currently being proposed, “the science underlying numerous drugs approved in the 21st century would not have been funded,” Incorvaia explains. The findings suggest that “massive cuts of the kind that are being contemplated right now could endanger the intellectual foundations of the drugs of tomorrow,” explains Professor Pierre Azoulay. 

A new study co-authored by MIT researchers finds that more than half of the drugs approved by the FDA since 2000 are connected to NIH research that would be impacted by proposed 40 percent budget cuts, reports Genetic Engineering & Biotechnology News. 

Using AI, researchers at MIT have developed new antibiotics for gonorrhoea and MRSA, two infections that are typically hard to treat. The team “trained the AI to help it learn how bacteria was affected by different molecular structures built of atoms in order to design new antibiotics,” writes Ruth Stainer for the Daily Mail. “[A]nything too similar to the current antibiotics available, or with the potential to be toxic to human beings, was eradicated.” 

Researchers at MIT used AI to “design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA,” reports ITV News. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says Prof. James Collins. 

Using generative AI, researchers at MT have designed new antibiotics to combat MRSA and gonorrhea, reports James Gallagher for the BBC. "We're excited because we show that generative AI can be used to design completely new antibiotics," says Prof. James Collins. "AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs."

A new study by MIT researchers has “identified the parts of the brain’s visual cortex that respond more when we look at things (rigid objects like a stone skipping or a bouncing ball) vs stuff (liquids or something more granular like sand). Understanding this distinction may help our brains better plan how to interact with various materials,” explains Lauren Baisas for Popular Science. “Understanding this distinction may help our brains better plan how to interact with various materials,” explains Baisas. 

Researchers at MIT have designed an implantable device that can be used to administer a dose of glucagon to protect Type 1 diabetics from hypoglycemia, reports Amir Khollam. “The device, about the size of a quarter, sits under the skin and releases a dose of glucagon when blood sugar levels dip too low,” explains Khollam. “It can be activated manually or triggered wirelessly by a sensor.” 

Researchers at MIT have developed a new HIV vaccine that could offer “strong protection with just one injection,” reports Ian Randall for Newsweek. “The vaccine includes two ‘adjuvants’—materials that help stimulate the immune system response,” explains Randall. “In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all.”